Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Hainan Shuangcheng Pharmaceuticals Co., Ltd. operates internationally, undertaking the entire lifecycle of synthetic peptide drugs and active pharmaceutical ingredients (APIs), from initial research and development through manufacturing to global market distribution. Its extensive product portfolio encompasses a wide array of injectable medications, including somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate. Additionally, the company provides vitamin B6. Founded in 2000, the firm is headquartered in Haikou, People's Republic of China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB